Table 3.
Comparison of clinical characteristics after anti-VEGF Treatment with PM-CNV.
| Characteristics | Type 1 | Type 2 | P | P1 | P2 |
|---|---|---|---|---|---|
| BCVA (LogMAR), median (IQR) | 0.45 (0.4–0.5) | 0.6 (0.53–0.7) | 0.001 a | <0.001 b | <0.001 b |
| CNV area, (mm2), median (IQR) | 0 (0–0.02) | 0.015 (0–0.026) | 0.125a | <0.001 b | <0.001 b |
| HRF height, (μm), median (IQR) | 0 (0–0) | 30.5 (0–80.75) | <0.001 a | 0.018 b | <0.001 b |
| Appearance of EZ | Intact = 20 | Intact = 15 | <0.001 c | —— | 0.021 c |
| Disrupted = 0 | Disrupted = 9 | ||||
| Absent =0 | Absent = 4 | ||||
| Appearance of RPE | Intact = 20 | Intact = 10 | <0.001 c | —— | 0.001 c |
| Disrupted = 0 | Disrupted = 12 | ||||
| Absent =0 | Absent = 6 |
PM, pathologic myopia; CNV, choroidal neovascularization; SD, standard deviation; BCVA, best corrected visual acuity; LogMAR, logarithm of the minimum angle of resolution; IQR, interquartile range; HRF, hyperreflective foci; EZ, ellipsoid zone; RPE, retinal pigment epithelium; P, type 1 vs. type 2 after treatment; P1, type 1 before and after treatment; P2, type 2 before and after treatment; P with statistical significance is shown in boldface; aMann - Whitney test; bWilcoxon signed rank test; cFisher exact text.